首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCGB3A2 |
| Uniprot No | Q96PL1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-93aa |
| 氨基酸序列 | FLINKVPLPVDKLAPLPLDNILPFMDPLKLLLKTLGISVEHLVEGLRKCV NELGPEASEAVKKLLEALSHLV |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCGB3A2重组蛋白的3篇参考文献及其简要概括：
1. **文献名称**: *"Secretoglobin 3A2 suppresses bleomycin-induced pulmonary fibrosis by inhibiting TGF-β signaling"*
**作者**: Chiba Y, et al.
**摘要**: 该研究通过重组SCGB3A2蛋白在小鼠模型中的应用，发现其能够抑制TGF-β信号通路，显著减轻博来霉素诱导的肺纤维化，表明其在抗纤维化治疗中的潜在作用。
2. **文献名称**: *"Recombinant SCGB3A2 protein inhibits lung adenocarcinoma progression by inducing apoptosis and suppressing EMT"*
**作者**: Kurotani R, et al.
**摘要**: 研究利用重组SCGB3A2蛋白处理肺癌细胞，发现其通过激活caspase通路诱导细胞凋亡，并抑制上皮-间质转化(EMT)，提示其在肺癌治疗中的临床应用价值。
3. **文献名称**: *"SCGB3A2 as a novel anti-inflammatory agent: Recombinant protein production and functional characterization in airway inflammation models"*
**作者**: Yamada M, et al.
**摘要**: 该文献报道了重组SCGB3A2蛋白在大肠杆菌中的高效表达与纯化方法，并验证其在气道炎症模型中通过抑制IL-6和TNF-α分泌发挥抗炎作用。
如需具体文献来源或补充更多研究，可进一步提供数据库(如PubMed)检索关键词或限定发表时间。
**Secretoglobin 3A2 (SCGB3A2)**, also known as uteroglobin-related protein 1 (UGRP1), is a small, secreted protein belonging to the secretoglobin family. This family is characterized by conserved structural features, including a hydrophobic binding pocket and the ability to form disulfide-linked dimers. SCGB3A2 is primarily expressed in epithelial tissues, notably in the respiratory tract (e.g., trachea, bronchioles) and reproductive organs, suggesting roles in mucosal immunity and tissue homeostasis.
Genetically located on human chromosome 5q31-q34. SCGB3A2 is regulated by transcription factors such as FOXA2 and NKX2-1. which are critical for lung development. Functionally, it exhibits anti-inflammatory and immunomodulatory properties, potentially through interactions with phospholipids or by modulating cytokine signaling. Studies link SCGB3A2 to conditions like pulmonary fibrosis, asthma, and certain cancers, where its expression is often dysregulated. For instance, reduced SCGB3A2 levels correlate with airway inflammation, while overexpression in cancers may influence tumor progression.
**Recombinant SCGB3A2 protein** is produced via heterologous expression systems, such as *E. coli* or mammalian cell lines, enabling large-scale purification for research. Its applications span *in vitro* and *in vivo* studies to dissect molecular mechanisms, develop diagnostic biomarkers, or explore therapeutic strategies. For example, recombinant SCGB3A2 has shown promise in mitigating lung injury in preclinical models, likely by suppressing pro-inflammatory pathways.
Despite progress, challenges remain in understanding its precise receptors, signaling cascades, and tissue-specific roles. Additionally, structural studies to resolve its ligand-binding dynamics could unlock therapeutic potential. Current research focuses on harnessing recombinant SCGB3A2 for targeted treatments in chronic respiratory diseases or as an adjuvant in anti-inflammatory therapies. However, clinical translation requires further validation of its efficacy, safety, and delivery mechanisms.
×
